- Trials with a EudraCT protocol (126)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
126 result(s) found for: Endometrial biopsy.
Displaying page 1 of 7.
EudraCT Number: 2014-000991-25 | Sponsor Protocol Number: Metform03 | Start Date*: 2014-09-23 | |||||||||||
Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Pre-surgical metformin for women with endometrial cancer: a randomised placebo controlled trial | |||||||||||||
Medical condition: Endometrial carcinoma or hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001382-40 | Sponsor Protocol Number: Metform01 | Start Date*: 2011-09-09 | |||||||||||
Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Proof of mechanism pre-surgical window trial of metformin in non-diabetic women with endometrial carcinoma: a feasibility study | |||||||||||||
Medical condition: Endometrial carcinoma or hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001732-38 | Sponsor Protocol Number: 1502 | Start Date*: 2015-09-14 | |||||||||||
Sponsor Name:CENTRE OSCAR LAMBRET | |||||||||||||
Full Title: EVALUATION OF SENTINEL NODE (SN) POLICY IN EARLY STAGE ENDOMETRIAL CARCINOMAS AT INTERMEDIATE AND HIGH RISK OF RECURRENCE: RANDOMIZED STUDY COMPARING SENTINEL NODE POLICY TO CURRENT FRENCH INITIAL ... | |||||||||||||
Medical condition: Intermediate-risk endometrioïd carcinomas : IAg3, IB(II)g1-2 High-risk endometrioïd carcinomas : IB-II g3 High-risk non endometrioïd carcinomas : I-II | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002443-21 | Sponsor Protocol Number: CO44195 | Start Date*: 2023-03-01 | ||||||||||||||||
Sponsor Name:F. HOFFMANN - LA ROCHE LTD. | ||||||||||||||||||
Full Title: A PHASE II, SINGLE-ARM STUDY OF GIREDESTRANT IN PATIENTS WITH GRADE 1 ENDOMETRIAL CANCER | ||||||||||||||||||
Medical condition: Grade 1 Endometrial Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003469-32 | Sponsor Protocol Number: UCL/13/0045 | Start Date*: 2014-10-13 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: A Single Arm Phase II trial of BMN 673 for inoperable, advanced endometrial cancer with retrospective PTEN, MSI and MRE11 analysis. | |||||||||||||
Medical condition: Inoperable, advanced, recurrent or metastatic endometrial cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004112-60 | Sponsor Protocol Number: D9311C00001 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or with... | |||||||||||||
Medical condition: Endometrial Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) GR (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004617-28 | Sponsor Protocol Number: | Start Date*: 2017-11-30 | |||||||||||
Sponsor Name:The University of Manchester | |||||||||||||
Full Title: A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination with Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy as Second-Line Therapy for Advanced/Metastatic Endometria... | |||||||||||||
Medical condition: Advanced or recurrent endometrial carcinoma or carcinosarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001352-21 | Sponsor Protocol Number: ABT-C5-2016 | Start Date*: 2016-09-19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Ability Pharmaceuticals, SL | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase I/ II, open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Squamous Cell Non-Small Cell Lung Cancer and advanced endometrial cancer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004061-13 | Sponsor Protocol Number: ESR21-21165 | Start Date*: 2022-06-09 | ||||||||||||||||
Sponsor Name:VHIO Vall d’Hebron Institute of Oncology | ||||||||||||||||||
Full Title: Single cell characterization of persistent cells upon treatment with durvalumab (MEDI4736) with or without tremelimumab in MSS and MSI colorectal and endometrial tumors | ||||||||||||||||||
Medical condition: MSS and MSI colorectal and endometrial tumors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000607-25 | Sponsor Protocol Number: KCP-330-024BGOG-EN5/ENGOT-EN5/SIEND | Start Date*: 2017-11-22 | |||||||||||||||||||||
Sponsor Name:Karyopharm Therapeutics Inc. | |||||||||||||||||||||||
Full Title: A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer | |||||||||||||||||||||||
Medical condition: Selinexor/placebo will be given as maintenance therapy after combination chemotherapy for patients with advanced endometrial cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) PL (Completed) IT (Trial now transitioned) GR (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024396-12 | Sponsor Protocol Number: CBEZ235C2201 | Start Date*: 2011-06-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Phase II, single-arm study of orally administered BEZ235 as second-line therapy in patients with advanced endometrial carcinoma | |||||||||||||
Medical condition: Patients who have experienced progression of disease after first-line antineoplasic treatment of advanced endometrial carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000266-35 | Sponsor Protocol Number: CTKI258A2211 | Start Date*: 2012-03-21 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: A phase II, open-label, single-arm, non-randomized, multi-center study to evaluate the efficacy of oral TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and... | |||||||||||||
Medical condition: Advanced and/or metastatic endometrial carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003009-24 | Sponsor Protocol Number: MK-7902-001 | Start Date*: 2020-03-18 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-... | |||||||||||||
Medical condition: Advanced Endometrial Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004387-35 | Sponsor Protocol Number: MK-3475-775/E7080-G000-309 | Start Date*: 2018-06-13 | |||||||||||
Sponsor Name:Eisai Ltd | |||||||||||||
Full Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with A... | |||||||||||||
Medical condition: Advanced Endometrial Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) ES (Ongoing) IE (Completed) GB (GB - no longer in EU/EEA) PL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022015-19 | Sponsor Protocol Number: CBKM120C2201 | Start Date*: 2011-04-26 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A | |||||||||||||
Full Title: Estudio de fase II, de una sola rama, de BKM120 administrado por vía oral como tratamiento de segunda línea en pacientes con carcinoma endometrial avanzado | |||||||||||||
Medical condition: Mujeres adultas con carcinoma endometrial avanzado cuya enfermedad ha progresado durante o después del tratamiento antineoplásico de primera línea para la enfermedad avanzada. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) BE (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004364-11 | Sponsor Protocol Number: 69HCL15_0321 | Start Date*: 2016-03-07 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: ENDOLA A PHASE I/II TRIAL TO ASSESS THE SAFETY AND EFFICACY OF METRONOMIC CYCLOPHOSPHAMIDE, METFORMIN AND OLAPARIB IN RECURRENT ADVANCED/METASTATIC ENDOMETRIAL CANCER PATIENTS | |||||||||||||
Medical condition: - Patients with histologically and/or cytologically documented endometrial carcinoma (type I or type II), recurrent after platinum-based chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001815-30 | Sponsor Protocol Number: SGUL/SGH 001 | Start Date*: 2006-06-05 | |||||||||||
Sponsor Name:St George's, University of London (SGUL) [...] | |||||||||||||
Full Title: Prevention Of Endometrial Tumours (POET) | |||||||||||||
Medical condition: Endometrial cancer/tumours in women with Hereditary Non-polyposis Colorectal Cancer (HNPCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023081-52 | Sponsor Protocol Number: ENGOT-EN2-DGCG | Start Date*: 2011-01-25 | ||||||||||||||||
Sponsor Name:Danish Gynaecological Cancer Group (DGCG) | ||||||||||||||||||
Full Title: A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer. | ||||||||||||||||||
Medical condition: Endometrial cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: DK (Completed) SE (Completed) BE (Completed) FI (Completed) AT (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) IT (Completed) NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002904-29 | Sponsor Protocol Number: INCB01158-203 | Start Date*: 2017-12-20 | |||||||||||||||||||||||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||||||||||||||||||||||
Full Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors. | |||||||||||||||||||||||||||||||||
Medical condition: Phase 1: Advanced or metastatic solid tumors Phase 2: Advanced/metastatic microsatellite stable colorectal cancer (MSS-CRC), biliary tract cancer (BTC), gastroesophageal cancer (GC), and endometri... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-002310-16 | Sponsor Protocol Number: LHinPOR001 | Start Date*: 2023-02-01 |
Sponsor Name:UZ Brussel | ||
Full Title: Endometrial gene expression profiles during ovarian stimulation with recombinant human FSH with or without the addition of recombinant human LH in genuine poor responders. | ||
Medical condition: Infertility | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
